ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aruvant partners with Lonza to manufacture sickle cell disease treatment
January 20, 2021Clinical-stage biopharmaceutical firm Aruvant Sciences and Lonza have entered a strategic long-term manufacturing agreement for the former’s one-time investigational gene therapy for sickle cell disease (SCD), ARU-1801. -
Aruvant Receives FDA Rare Pediatric Disease Designation for Sickle Cell Treatment
January 13, 2020Aruvant announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to ARU-1801, Aruvant's investigational therapy for the treatment of sickle cell disease.
Pharma Sources Insight January 2025
